Brief: Sosei Heptares Says Partner Tempero Bio Received FDA Clearance To Advance Clinical Development Of TMP-301
05/01/2023 07:43
Jan 5 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES PARTNER TEMPERO BIO RECEIVED FDA CLEARANCE
TO
ADVANCE CLINICAL DEVELOPMENT OF TMP-301 FOR TREATMENT OF
ALCOHOL, SUBSTANCE USE DISORDERS
Source text for Eikon: ID:nGNX8Ncw2P
Further company coverage: 4565.T
((Reuters.Brief@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up